Company: AGIO
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001439222-25-000116
Chunk: 137

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 137
---
 with performance and market vesting conditions, respectively, that were not deemed probable as of September 30, 2025 are not considered to be common stock equivalents.We utilize the control number concept in the computation of diluted earnings per share to determine whether potential common stock equivalents are dilutive. The control number used is net (loss) income from continuing operations. The control number concept requires that the same number of potentially dilutive securities applied in computing diluted earnings per share from continuing operations be applied to all other categories of income or loss, regardless of their anti-dilutive effect on such categories. Since we had a net loss for the three and nine months ended September 30, 2025, no dilutive effect was recognized in the calculation of loss per share and basic and diluted net loss per share was the same for those periods.The following is a reconciliation of basic weighted-average number of common shares used in computing net (loss) income per share to diluted weighted-average number of common shares used in computing net (loss) income per share for the periods indicated:Three Months Ended September 30,Nine Months Ended September 30,2025202420252024Basic shares58,139,277 56,939,403 57,846,173 56,709,318 Effect of dilutive securitiesStock options— 557,300 — 231,082 Restricted stock units— 927,149 — 626,208 Performance-based stock units— — — 11,793 Employee stock purchase plan shares— 8,944 — 2,981 Diluted shares58,139,277 58,432,796 57,846,173 57,581,382 

16

The following common stock equivalents were excluded from the calculation of diluted net (loss) income per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:Three Months Ended September 30,Nine Months Ended September 30,2025202420252024Stock options6,271,947 3,463,344 6,271,947 5,176,610 Restricted stock units2,055,122 — 2,055,122 90,480 Employee stock purchase plan shares81,191 3,139 81,191 4,393 Total common stock equivalents8,408,260 3,466,483 8,408,260 5,271,483